Substance
ID:449300
Names and Identifiers
IUPAC name
2-amino-9-[(2-hydroxyethoxy)methyl]-6,9-dihydro-1H-purin-6-one
Synonyms
AcycloguanosineZoviraxSupraviranMirolexZyclirVirovirAcyclovirHerpetadSoothelipAciclovirAviraxGeavirMilavirActivirCycloviranVirasorb
IUPAC Traditional name
2-amino-9-[(2-hydroxyethoxy)methyl]-6,9-dihydro-1H-purin-6-one
Registration numbers
CAS Number
Properties
Pharmacology Properties
Mechanism of Action
and finally to the triphosphate by phosphoglycerate kinase, phosphoenolpyruvate carboxykinase, and pyruvate kinase.
Aciclovir triphosphate competitively inhibits viral DNA polymerase and competes with the natural deoxyguanosine triphosphate, for incorporation into viral DNA.
Viral (HSV-1, HSV-2 and VZV) thymidine kinase converts aciclovir to the aciclovir monophosphate, which is then converted to the diphosphate by cellular guanylate kinase,
Guanosine analog that acts as an antimetabolite.
Once incorporated, aciclovir triphosphate inhibits DNA synthesis by acting as a chain terminator.
Product Information
Application(s)
Used especially against herpes.
Antiviral agent.
Molecule Details
No Data Available
Click here to submit data
Molecular Spectra
No Data Available
Click here to submit data
References
• Jennings, R. et al., Antimicrob. Agents Chemother., 1999, 43, 53-61, (acyclovir elaidate)
• Plass, M. et al., J.C.S. Perkin 2, 1999, 2641-2646, (uv, pmr, ir, Raman)
• Ger. Pat., 1976, 2 539 963; CA, 84, 180300p, (synth)
• Birnbaum, G.I. et al., Can. J. Chem., 1984, 62, 2646, (cryst struct)
• Alhede, B. et al., J.O.C., 1991, 56, 2139, (synth, cmr)
• Buck, I.M. et al., Tetrahedron, 1994, 50, 9195-9206, (synth)
• Stimac, A. et al., Synthesis, 1990, 461-464, (synth)
• Gao, H. et al., Synth. Commun., 2001, 31, 1399-1419, (synth)
• Arndt, K.A. et al., J. Am. Acad. Dermatol., 1988, 18, 188, (adverse effects)
• Martindale, The Extra Pharmacopoeia, 32nd edn., Pharmaceutical Press, 1999, 602; 628
• Ormrod, D. et al., Drugs, 2000, 59, 839-863; 1317-1359
• Lewis, R.J., Sax's Dangerous Properties of Industrial Materials, 8th edn., Van Nostrand Reinhold, 1992, AEC700; AEC725
• Elion, G.B. et al., Proc. Natl. Acad. Sci. U.S.A., 1977, 74, 5716, (pharmacol)
• Krasny, H.C. et al., Biochem. Pharmacol., 1986, 35, 4339, (metab)
• U.K. Pat., 1993, Norsk Hydro A/S, 2 260 319; CA, 119, 271633g, (acyclovir elaidate)
• Rees, P.J. et al., J. Antimicrob. Chemother., 1986, 18, 215-222, (pharmacokinet)
• Gao, H. et al., Synthesis, 2000, 329-351, (rev)
• Eur. Pat., 1984, Wellcome, 108 285; CA, 101, 192401e, (Desciclovir, synth, pharmacol)
• Krenitsky, T.A. et al., Proc. Natl. Acad. Sci. U.S.A., 1984, 81, 3209-3213, (synth, pharmacol)
• Chu, C.K. et al., J. Het. Chem., 1986, 23, 289, (rev)
• Petty, B.G. et al., Antimicrob. Agents Chemother., 1987, 31, 1317-1322, (pharmacokinet)
• Fiddian, A.P., Appl. Virol., 1984, 103, (rev, pharmacol)
• Reardon, J.E. et al., Adv. Pharmacol., 1991, 22, 1, (rev)
• Wagstaff, A.J. et al., Drugs, 1994, 47, 153, (rev)
• Kelley, J.L. et al., J. Het. Chem., 1986, 23, 271, (synth)
• Radl, S. et al., Cesk. Farm., 1987, 36, 58, (synth)
• Matsumoto, H. et al., Chem. Pharm. Bull., 1988, 36, 1153, (synth)
• De Miranda, P. et al., Antiviral Chem. Chemother., 1992, 3, 1, (metab, rev)